Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “Corvus Pharmaceuticals, Inc.”

14 pharma patents match "Corvus Pharmaceuticals, Inc." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 14
Index total 30,257
Page 1 / 1

Quick answer

This filtered view shows 14 pharmaceutical patents matching "Corvus Pharmaceuticals, Inc." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

14 results for “Corvus Pharmaceuticals, Inc.” · 30,257 patents in full index Clear search

  1. US 12351644

    Anti-CD73 antibodies

    Corvus Pharmaceuticals, Inc. · Granted Jul 8, 2025 · Expires Jul 3, 2045

    granted
  2. US 12174192

    Methods for detecting and treating cancers having adenosine pathway activation

    Corvus Pharmaceuticals, Inc. · Granted Dec 24, 2024 · Expires Dec 19, 2044

    granted
  3. US 12116635

    Methods for detecting and treating cancers having adenosine pathway activation

    Corvus Pharmaceuticals, Inc. · Granted Oct 15, 2024 · Expires Oct 10, 2044

    granted
  4. US 12023337

    Methods of treating cancer

    Corvus Pharmaceuticals, Inc. · Granted Jul 2, 2024 · Expires Jun 27, 2044

    granted
  5. US 11897874

    Compounds and methods for modulating Interleukin-2-inducible T-cell kinase

    Corvus Pharmaceuticals, Inc. · Granted Feb 13, 2024 · Expires Feb 8, 2044

    granted
  6. US 11859007

    Humanized anti-CD73 antibodies

    Corvus Pharmaceuticals, Inc. · Granted Jan 2, 2024 · Expires Dec 28, 2043

    granted
  7. US 11266649

    Pharmaceutical formulations

    Corvus Pharmaceuticals, Inc. · Granted Mar 8, 2022 · Expires Mar 3, 2042

    granted
  8. US 11254686

    Compounds and methods for modulating adenosine A2B receptor and adenosine A2A receptor

    Corvus Pharmaceuticals, Inc. · Granted Feb 22, 2022 · Expires Feb 17, 2042

    granted
  9. US 11040040

    Methods of treating cancer

    Corvus Pharmaceuticals, Inc. · Granted Jun 22, 2021 · Expires Jun 17, 2041

    granted
  10. US 11008314

    Compounds and methods for modulating interleukin-2-inducible t-cell kinase

    Corvus Pharmaceuticals, Inc. · Granted May 18, 2021 · Expires May 13, 2041

    granted
  11. US 10912776

    Methods of treating cancer

    Corvus Pharmaceuticals, Inc. · Granted Feb 9, 2021 · Expires Feb 4, 2041

    granted
  12. US 10870652

    Compounds and methods for modulating bruton's tyrosine kinase

    Corvus Pharmaceuticals, Inc. · Granted Dec 22, 2020 · Expires Dec 17, 2040

    granted
  13. US 10822426

    Humanized anti-CD73 antibodies

    Corvus Pharmaceuticals, Inc. · Granted Nov 3, 2020 · Expires Oct 29, 2040

    granted
  14. US 10793636

    Anti-CD73 antibodies

    Corvus Pharmaceuticals, Inc. · Granted Oct 6, 2020 · Expires Oct 1, 2040

    granted